ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO601

Outcomes of COVID-19 Infection in Patients with ANCA-Associated Vasculitis Receiving Avacopan Therapy

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Aqeel, Faten, Johns Hopkins University, Baltimore, Maryland, United States
  • Zonozi, Reza, Harvard University, Cambridge, Massachusetts, United States
  • Jeyabalan, Anushya, Harvard University, Cambridge, Massachusetts, United States
  • Sauvage, Gabriel, Harvard University, Cambridge, Massachusetts, United States
  • Niles, John, Harvard University, Cambridge, Massachusetts, United States
  • Geetha, Duvuru, Johns Hopkins University, Baltimore, Maryland, United States

The complement C5a-C5aR signaling axis plays a crucial role in the pathogenesis of ANCA-associated vasculitis (AAV) and COVID-19 infection. Avacopan, a C5aR antagonist is approved as an adjunct therapy for remission induction in AAV. Vilobelimab, a C5a antibody was granted Emergency Use Authorization by the FDA for severe COVID-19 infection. In AAV, COVID-19 infection poses an increased mortality risk. Additionally, the risk of severe COVID-19 infection is increased in patients receiving rituximab and glucocorticosteroids.


We performed an observational, retrospective study examining outcomes of patients with AAV treated with avacopan and who had COVID-19 infection. Data on ANCA type, immunosuppressive treatment, COVID-19 course, and COVID-19 vaccination status were retrieved after a review of the electronic medical records.


A total of 7 patients were included. The mean (SD) age was 65.1 (±17.5) years old. Four patients had MPO-AAV and 3 patients had PR3-AAV. Two patients had a relapsing disease, and the rest had a new diagnosis of AAV. Six patients received at least 3 COVID-19 vaccines and a single patient received two COVID-19 vaccines. Five patients received a combination of rituximab, cyclophosphamide, glucocorticoids, and avacopan, whereas 2 patients received rituximab, glucocorticoids, and avacopan. The mean (SD) time from the date of initiation of induction immunosuppression to avacopan initiation was 20 (±21.5) days. The mean (SD) time from avacopan initiation to COVID-19 infection was 110 (±62) days. At the time of COVID-19 infection, all patients remained on rituximab therapy. The mean (SD) time between the last rituximab dose and the onset of COVID-19 infection was 63.8 (±57.1) days. Avacopan was continued in all patients. COVID-19 treatment included Paxlovid (n=3), Bebtelovimab (n=1), Molnupiravir (n=1), remdesivir and dexamethasone (n=1), and no treatment (n=1). All patients had mild symptoms except one patient who was hospitalized and died from severe COVID-19 infection.


COVID-19 clinical course appears to be mild in the majority AAV patients treated with avacopan, with a single patient experiencing severe COVID-19 infection and death. More studies are needed to explore the interplay between C5a blockade and infectious complications from SARS-CoV-2.